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Transforming growth factor alpha immunoreactivity in human 
gallbladder and extrahepatic biliary tract tumours 
C. Soon Lee 
Department of Pathology, The University of Melbourne, Australia 
Aims. Transforming rowth factor alpha (TGF-alpha), a protein structurally similar to epidermal growth factor 
(EGF), is implicated in the development of many human tumours. This study examines the expression of TGF-alpha 
in gallbladder and extrahepatic biliary tract tumours in which EGFR expression has been previously shown to be 
important. 
Methods. A monoclonal antibody to the TGF-alpha protein was used to investigate the immunohistochemical 
expression of TGF-alpha in carcinoma of the gallbladder (11 = 13), common bile duct (CBD) (n = 6) and ampulla of 
Vater (n = 8). Tissues from cases of chronic cholecystitis (n = 11), gallbladder dysplasia 01 = 3) and adenoma 01 = I), 
and ampullary carcinoma hi situ (CIS) (n=3) were used as non-malignant controls. These cases were previously 
studied for EGFR expression. 
Results. TGF-alpha overexpression, defined as intense immunoreactivity in more than two-thirds of cells 
immunostained for TGF-alpha, was present in most gallbladder carcinomas (n= 10; 77%) but with no significant 
differences in expression between different umour grades. None of the cases of gallbladder dysplasia or chronic 
cholecystitis had strong TGF-alpha expression and this was significantly different from the carcinomas (P=0.013 
and P=0.0001, respectively; Z" test), although a few cases of chronic cholecystitis showed weak (n =4), moderate 
(n=6) or no (n= I) immunoreactivity. A few ampullary carcinomas (n=2; 25%) and CIS 01= 1; 33%), and half of 
the CBD carcinomas (50%) had strong TGF-alpha immunoreactivity. There was correlation between TGF-alpha 
and EGFR immunoreactivity n the tumour cases (r= 0.70, ia= 0.49, P = 0.0001; simple regression analysis), although 
the rate of EGFR immunoreactivity in CBD and ampullary carcinomas was somewhat higher than that of TGF- 
alpha. However, no statistically significant correlation between TGF-alpha expression with patient survival or tumour 
recurrence ( r=0.11, /=0.012,  P=0.65; simple regression analysis) was found. 
Conclusions. Increased TGF-alpha expression occurs more frequently in gallbladder carcinoma than in gallbladder 
dysplasia, chronic cholecystitis, CBD or ampullary tumour, with no specific relationship to tumour grade, suggesting 
that TGF-alpha overexpression ccurs early in the development of gallbladder cancers, and that biliary tract cancers 
have a different molecular origin. Correlation was found between TGF-alpha and EFGR expression in gallbladder 
and biliary tract tumours. 
Key words: TGF-alpha; EGF receptor; gallbladder neoplasms; biliary tract neoplasms; immunohistochemistry; tumour 
markers; tyrosine kinase. 
Introduction 
Cancers of the gallbladder and extrahepatic bile ducts are 
relatively uncommon with 135 new cases diagnosed in 1992 
in the state of New South Wales, Australia. These tumours 
account for about 1.2°/,, of all cancer-related deaths and 
have a peak incidence during the seventh decade of life) 
Males and females are affected with almost equal frequency. 
Both carcinoma of the gallbladder and extrahepatic bile 
ducts have a poor prognosis with 5-year survival rates of 5 
and 3.6%, respectively. 24 
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Increased expression of transforming growth factor-alpha 
(TGF-alpha) is found in several types of tumour, s ~6 TGF- 
alpha is structurally and functionally similar to epidermal 
growth factor (EGF) and both growth factors bind to the 
epidermal growth factor (EGFR)) 7 20 The role of TGF- 
alpha in the development of human cancers may be related 
to its responsiveness and mitogenic effects in many human 
tissues that possess EGFRs. "j 
Overexpression of the EGFR has been previously 
reported as important in gallbladder and biliary tract 
cancers-'-' and another histogenetically related tumour, 
pancreatic carcinoma." This study attempts to demonstrate 
and examine the expression of TGF-alpha in gallbladder 
and biliary tract cancers, and assess its prognostic value, 
using cases of chronic cholecystitis as the non-neoplastic 
control group. 
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Mater ia l s  and  methods  
Tissue 
Paraffin-embedded, archival tissues from patients with 
gallbladder adenocarcinoma (n = 13), dysplasia (n = 3) and 
adenoma (n= I), chronic cholescystitis (n= 11), common 
bile duct carcinoma (n=6), together with ampullary 
carcinoma (n=6) and carcinoma in situ (C1S) (n=3) were 
studied. The gallbladder adenocarcinomas were further 
classified as moderate-to-poorly differentiated (n=4) or 
poorly differentiated (n=9). The moderate-to-poorly 
differentiated a enocarcinomas were identified as those with 
areas of both moderate glandular differentiation and 
anaplasia. The poorly differentiated tumours consisted 
predominantly of solid sheets of tumour cells with little or 
no evidence of glandular differentiation. 
Table 1. Summary of TGF-alpha immunostaining results in 
gallbladder and biliary tract neoplasia, and chronic cholecystitis 
lmmunoreactivity 
Diagnosis n Negative Weak Moderate Strong 
Gallbladder 
adenocarcinoma 
Moderately 
differentiated 4 - -  - -  I 3 
Poorly differentiated 9 - -  1 1 7 
Gallbladder adenoma I - -  - -  - -  I 
Gallbladder dysplasia 3 - -  1 2 - -  
Chronic cholecystitis I I I 4 6 - -  
Common bile duct 
carcinoma 6 - -  - -  3 3 
Ampullary carcinoma 8 1 1 4 2 . 
Amupullary carcinoma 
in situ 3 - -  2 - -  I 
Abbreviations: n: number of cases. TGF-alpha: transforming 
growth factor alpha. 
hnnmnohistochemistry 
lmmunohistochemistry was performed on sections which 
had been cut at 41am, mounted on 5-aminopropyl- 
triethoxysilane (AAS)-coated slides and allowed to dry 
overnight. Two adjacent sections were used for the study, 
one for immunostaining and the other as negative control. 
After dewaxing in xylene, blocking of endogenous 
peroxidase, washing in phosphate-buffered saline (PBS), 
and blocking of non-specific binding of secondary antibody 
with normal swine serum, routine streptavidin-biotin- 
peroxidase immunostaining with diaminobenzidine was 
applied to the sections incubated overnight with a 
monoclonal antibody to TGF-alpha (Oncogene Science 
lnc, Manhasset, NY; clone GSI0) (1:100, dilution). 
Immunohistochemistry for EGFR (Serotec; distributed by 
Australian Laboratory Science, Rockdale, NSW, Australia; 
clone MCA-571) (1:1500, dilution) was performed on the 
same cases as previously described, z-'The primary antibody 
was substituted with PBS in sections used as negative 
controls. The sections were counterstained with Harris 
Haematoxylin. 
lmmunohistochemical staining of cells was assessed 
according to both the intensity and proportion of cells 
stained. The intensity was scored on a semiquantitative 
4-point scale as follows: 0=no staining; i=weak; 2= 
moderate; and 3=intense staining. The proportion of 
cells staining was also scored on a 4-point scale: 0=no 
cells staining; l= less  than one-third of cells staining; 
2=between one-third and two-thirds of cells staining; 
3=more  than two-thirds of cells staining. An 
immunostaining score, ranging from 0 to 6, was derived 
by adding the above two scores, lmmunohistological 
expression of TGF-alpha was then classified according 
to the immunostaining score as follows: immunostaining 
score of 0=no expression (N); l -2=weak  (W); 3--4= 
moderate (M); >4 = strong (S) expression. Cases classified 
as having strong TGF-alpha immunoreactivity are those 
that demonstrate staining stronger than that observed in 
the normal gallbladder epithelium in cases of chronic 
cholecystitis. 
Statistical analysis 
Categorical variables were analysed with the chi-squared 
(;(2) contingency test. Only P-values of less than 0.05 were 
considered significant. 
Resu l ts  
Overexpression of TGF-alpha was defined as strong 
cytoplasmic mmunostaining of cells and this was found in 
most of the cases of gallbladder adenocarcinoma (n= I0; 
77%) (Table 1; Fig. 1). The majority of the poorly 
differentiated (n=7; 78%) and moderately differentiated 
gallbladder carcinomas (n=3; 75%) showed TGF-alpha 
overexpression. However, the differences in TGF-alpha 
expression between the different grades of gallbladder 
carcinomas were not statistically significant (P=0.91, ;(2 
test). 
In contrast, none of the cases of gallbladder dysplasia 
demonstrated strong expression of TGF-alpha and this is 
statistically significantly different to the carcinoma cases 
(P=0.013; ~ test). Similarly, the cases of chronic 
cholecystitis used as non-neoplastic controls showed weak 
(n =4), moderate (n =6) or no (n = 1) immunoreactivity and 
none had evidence of TGF-alpha overexpression. 
The difference in TGF-alpha immunoreactivity between 
gallbladder cancers and chronic cholecystitis was significant 
(P=0.0001; ;(2 test). 
Only a minority of the ampullary carcinomas (n =2; 25%) 
and CIS (n=l ;  33%), and half of the CBD carcinomas 
(50%) (Fig. 2) showed strong immunoreactivity to the TGF- 
alpha protein. 
There was statistically significant correlation between 
TGF-alpha expression and EGFR immunoreactivity 
obtained in a previous study 22 of the same tumour cases 
(r=0.70, r2=0.49, P=0.0001; simple regression analysis). 
In gallbladder carcinomas the proportion of increased TGF- 
alpha immunoreactivity (77%) was comparable to that of 
EGFR (100%). However, EGFR immunoreactivity n CBO 
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Fig. 1. Strong TGF-alpha immunoreactivity in the cytoplasm of neoplastic cells in a gallbladder adenocarcinoma (Immunoperoxidase, x 200). 
Fig. 2. Strong cytoplasm TGF-alpha immunostaining of neoplastic ells in a common bile duct carcinoma (lmmunoperoxidase, x 200). 
TGF-alpha expression in gallbladder and biliary tract cancers 41 
(86%), ampullary (67%) carcinomas, appears to be 
somewhat higher than that of TGF-alpha. 22 
However, there was no statistically significant correlation 
between TGF-alpha expression with patient survival or 
tumour recurrence (r=0.11, r2=0.012, P=0.65; simple 
regression analysis). 
Discussion 
Overexpression of TGF-alpha, a polypeptide with 
significant homology to EGF, ~8 is associated with cell 
proliferation shown experimentally in cell lines which 
possess EGFR. 2~ Neoplastic transformation f cells by TGF- 
alpha involves autocrine stimulation of cells 23 in which cells 
with surface EGFR are stimulated to grow when either 
TGF-alpha or EGF binds to the receptors. 23'24 TGF-alpha 
has been shown to be important in the development of 
many human cancers. 5 ,,.2s .~J In some tumours, TGF-alpha 
is implicated in their progression to a less differentiated 
state. 7 Increased levels of serum TGF-alpha are noted in 
several types of gastrointestinal cancers such as gastric, 
pancreatic and colorectal carcinomas/3 
The current study has demonstrated a statistically 
significant rate of increase in TGF-alpha immunoreactivity 
in gallbladder carcinomas than in gallbladder dysplasia or 
in cases of chronic cholecystitis. However, there was no 
significant difference in the expression of TGF-alpha 
between the different grades of gallbladder carcinomas. 
These findings suggest hat increased expression of TGF- 
alpha may be important in the early development rather 
than the progression of gallbladder carcinoma. On the other 
hand, TGF-alpha does not appear to be important in 
ampullary or CBD carcinoma with only a minority of these 
tumours displaying strong immunoreactivity to the TGF- 
alpha protein. 
in common with the current study, increased expression 
of TGF-alpha is observed to be an early event in gastric 
carcinogenesis) 2 Similarly, immunohistochemical detection 
of TGF-alpha is present in 95% of pancreatic ancers, a 
tumour that is histogenetically related to gallbladder and 
biliary tract cancers." The immunostaining is cytoplasmic 
with membrane accentuation." Although TGF-alpha is also 
implicated in the development of pancreatic arcinoma, 
there is no report to indicate that TGF-alpha is important 
in its progression." Of interest, TGF-alpha immuno- 
reactivity in squamous cell carcinoma of the larynx is found 
mostly in the better differentiated areas. ~~ 
However, no statistically significant correlation between 
TGF-alpha expression with patient survival or tumour 
recurrence (r= 0.11, r 2 = 0.012, P = 0.65; simple regression 
analysis) is found. This may be related to the small number 
of cases with adequate clinical follow-up examined in the 
current study. Further studies with longer follow-up in a 
larger series may be required to elucidate the prognostic 
significance of TGF-alpha expression i these tumour types. 
The correlation between TGF-alpha expression and 
EGFR immunoreactivity n the gallbladder and biliary tract 
carcinomas i consistent with the current concept of cancer 
development in which there is a sequential process of 
multiple genetic events with activation of several growth 
factors and inactivation of tumour suppressor genes. ~'~5 
However, the higher rate of TGF-alpha overexpression i  
gallbladder carcinomas than in CBD (50%), ampullary 
(25%) carcinomas and yet a similar ate of EGFR expression 
in all of these tumour types indicate that the role of TGF- 
alpha and EGFR in these tumours is complex. This may 
be explained by the possible activation of EGFRs by an 
autocrine mechanism involving EGF, EGFR and TGF- 
alpha that has been shown in previous tudies of other types 
of tumours. 23"24 Moreover, the current findings also support 
the possibility that the molecular and genetic events leading 
to the development of gallbladder cancers may be different 
from those in extrahepatic biliary tract tumours. 
In summary, this study has demonstrated increased TGF- 
alpha expression i  the majority of gallbladder carcinomas 
with no specific relationship to tumour grade suggesting 
that although it may be important in the development of 
gallbladder carcinomas, it may not be important in their 
progression, lmmunohistochemical detection of TGF-alpha 
does not appear to be of prognostic value in gallbladder 
and biliary tract carcinomas. There is significant correlation 
between TGF-alpha and EGFR expression in gallbladder 
and biliary tract carcinomas although TGF-alph'a 
overexpression is lower in the latter tumours, suggesting 
that EGFR may be activated by another mechanism in 
those tumours. 
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